CARVYKTI is winning, but the stock asks a lot
- CARVYKTI is the business, with Q1 2026 global net trade sales of $597 million.
- Manufacturing looks much better, with a 99% success rate and about 29 days median turnaround in Q1 2026.
- Earlier-line use is growing, as second and third line patients reached 41% of U.S. apheresis volume in Q1 2026.
- Q1 gross margin fell to 41% because of Raritan expansion costs, and management guided above 50% for Q2.
- The main test is whether community hospitals can keep adding patients without safety, cost, or competition problems.
A strong drug with a price test
Legend's bull case is simple. CARVYKTI is becoming one of the most important treatments for relapsed or refractory multiple myeloma, a blood cancer. It is a CAR-T therapy, which means a patient's own immune cells are changed so they can attack cancer cells.
The biggest old worry was supply. That risk has eased. In Q1 2026, Legend reported a 99% manufacturing success rate, about 29 days median turnaround, and more than 95% on-time order releases. That matters because a great cell therapy cannot grow if patients wait too long.
Growth is moving into earlier treatment. In Q1 2026, second and third line patients were 41% of U.S. apheresis volume, up from 29% a year earlier. The company says 2L-4L patients are now about two-thirds of the business and could move toward three-quarters.
The bear case is not that CARVYKTI is weak. It is that expectations are high. Q1 gross margin fell to 41% from 57% because of one-time Raritan expansion costs, with management guiding back above 50% in Q2. If community demand, margins, or competitor pressure disappoint, the stock may have less room for error.
One partner, one main product
Legend makes money mainly through its Janssen, or Johnson & Johnson, collaboration for CARVYKTI. Outside China, the companies share pre-tax profits and losses equally. In Greater China, Legend keeps or bears 70% of pre-tax profits or losses.
Janssen books sales in most markets, while Legend records its share as collaboration revenue. In 2025, collaboration revenue was $944.8 million out of total revenue of $1.0289 billion. License and other revenue was much smaller at $84.1 million.
The model improves as volume grows because the CARVYKTI franchise became profitable in 2025. But the company is still not fully past the investment phase. Legend reported a 2025 net loss of $296.8 million and had accumulated losses of $1.9585 billion at year-end.
The outpatient strategy is a key part of the story. CARVYKTI's delayed cytokine release syndrome profile helps more patients get treated outside the hospital. Management has said outpatient use is about half of the business, which can make treatment easier to scale.
CARVYKTI first, pipeline later
CARVYKTI
CARVYKTI is Legend's core approved therapy for multiple myeloma. It is approved in the U.S. and Europe for patients after at least one prior line of therapy, with broader later-line use in markets such as China and Australia.
CARTITUDE-5 and CARTITUDE-6
These trials push CARVYKTI into earlier myeloma treatment settings. Success would widen the patient pool, but early-line use must still prove safety, access, and payer support.
CARTITUDE-10
This study explores a fludarabine-free regimen. The goal is to reduce neurotoxicity risk while keeping CARVYKTI's cancer-fighting effect.
LB2501
LB2501 is an in vivo CD19/CD20 program for non-Hodgkin lymphoma. Initial clinical data were expected around midyear, and the program gained attention after J&J stopped its own ex vivo CD19/20 effort.
LB2505
LB2505 targets BCMA using an in vivo approach for autoimmune disease and multiple myeloma. It is earlier stage than CARVYKTI, but it could matter if in vivo delivery makes cell therapy simpler.
LB2102 and solid tumor work
Legend licensed LB2102, a DLL-3 focused CAR-T program, to Novartis. The 2025 filing says Legend recognized Novartis license revenue over time as it conducts a Phase 1 trial.
Revenue is highly concentrated
The mix is based on fiscal 2025 revenue in Legend's Form 20-F. Collaboration revenue tied to CARVYKTI made up almost all sales, so this is not a diversified revenue base.
What could break the thesis
Community rollout stalls
High impact · Medium oddsThe next leg of growth depends on reaching more community hospitals and local oncology practices. If local sites cannot handle referrals, monitoring, or logistics, earlier-line demand may grow slower than expected.
Margin recovery misses guidance
Medium impact · Medium oddsQ1 2026 gross margin on net product sales fell to 41% because of one-time costs tied to the expanded Raritan site. Management said Q2 should move back above 50%. If that does not happen, profitability in 2026 becomes harder to trust.
Anito-cel pressures the market
Medium impact · Medium oddsArcellx and Gilead's anito-cel is the main named competitive threat. The FDA gave it a standard review, which Legend views as a sign it may not be seen as clearly superior. Even so, a clean approval and strong launch could pressure CARVYKTI referrals.
Neurotoxicity concerns return
High impact · Low oddsCAR-T therapies can cause serious side effects, including delayed neurologic problems. Legend is trying to reduce this risk with better bridging therapy, monitoring, and trials such as CARTITUDE-10. A new safety signal would hurt doctor comfort, especially in earlier lines.
In vivo data disappoints
Medium impact · Medium oddsLB2501 and LB2505 are important because in vivo cell therapy could be easier than taking cells out of the body and modifying them in a lab. But these programs are early. Weak data would not break CARVYKTI, but it would shrink the long-term pipeline story.
In one breath
What is Legend Biotech best known for?
Legend is best known for CARVYKTI, a BCMA-targeted CAR-T therapy for multiple myeloma. It is the company's first and only approved product.
How does Legend Biotech make money?
Most revenue comes from the Janssen collaboration for CARVYKTI. In 2025, collaboration revenue was $944.8 million, compared with $84.1 million of license and other revenue.
Why does manufacturing matter so much for CARVYKTI?
CARVYKTI is made from each patient's own cells, so speed and reliability matter. In Q1 2026, Legend reported a 99% manufacturing success rate and about 29 days median turnaround.
Is Legend Biotech profitable?
The CARVYKTI franchise became profitable in 2025, and management expects company-wide adjusted profitability in 2026. On a reported basis, Legend still had a 2025 net loss of $296.8 million.